Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1A | P07327 | 1/20 | 0.51 |
| ▸ | KIT | P10721 | 1/20 | 0.51 |
| ▸ | FLT1 | P17948 | 1/20 | 0.51 |
| ▸ | FLT4 | P35916 | 1/20 | 0.51 |
| ▸ | KDR | P35968 | 1/20 | 0.51 |
| ▸ | ABL2 | P42684 | 1/20 | 0.51 |
| ▸ | PYGL | P06737 | 1/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 8/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 8/20 | 0.41 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.38 |
| ▸ | NHERF1 | O14745 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Seco-Cbi-Indole SCHEMBL29468891 | 1.00 | ADH1A (0.51) | ADH1AKITFLT1FLT4KDR | |
| SCHEMBL14586778 | 0.93 | ADH1A (0.49) | ADH1AKITFLT1FLT4KDR | |
| SCHEMBL12842016 | 0.93 | ADH1A (0.49) | ADH1AKITFLT1FLT4KDR | |
| SCHEMBL12508919 | 0.93 | ADH1A (0.49) | ADH1AKITFLT1FLT4KDR | |
| SCHEMBL436461 | 0.93 | ADH1A (0.49) | ADH1AKITFLT1FLT4KDR | |
| SCHEMBL15765316 | 0.93 | KDM1A (0.43) | ADH1AKITFLT1FLT4KDR | |
| SCHEMBL13669050 | 0.92 | ADH1A (0.50) | ADH1AKITFLT1FLT4KDR | |
| SCHEMBL12126075 | 0.91 | ADH1A (0.49) | ADH1AKITFLT1FLT4KDR | |
| SCHEMBL14665653 | 0.91 | PYGL (0.43) | ADH1AKITFLT1FLT4KDR | |
| SCHEMBL14669467 | 0.91 | PYGL (0.43) | ADH1AKITFLT1FLT4KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9586974-B2 | Cyclic N-acyl O-amino phenol CBI derivative | THE SCRIPPS RESEARCH INSTITUTE (US) | 2017-03-07 | — | — | US | disclosed |
| US-20160016972-A1 | Cyclic N-Acyl O-Amino Phenol CBI Derivative | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-01-21 | — | — | US | disclosed |
| WO-2014160586-A1 | CYCLIC N-ACYL O-AMINO PHENOL CBI DERIVATIVE | THE SCRIPPS RESEARCH LINSTITUTE (US) | 2014-10-02 | — | — | WO | disclosed |
| EP-2227087-B1 | CBI DERIVATIVES SUBJECT TO REDUCTIVE ACTIVATION | SCRIPPS RESEARCH INST (US) | 2013-10-09 | — | — | EP | disclosed |
| US-8377981-B2 | CBI derivatives subject to reductive activation | THE SCRIPPS RESEARCH INSTITUTE (US) | 2013-02-19 | — | — | US | disclosed |
| US-8377981-B2 | CBI derivatives subject to reductive activation | THE SCRIPPS RESEARCH INSTITUTE (US) | 2013-02-19 | — | — | US | disclosed |
| US-20110112163-A1 | CBI DERIVATIVES SUBJECT TO REDUCTIVE ACTIVATION | SCRIPPS RESEARCH INSTITUTE, THE | 2011-05-12 | — | — | US | disclosed |
| US-20110112163-A1 | CBI DERIVATIVES SUBJECT TO REDUCTIVE ACTIVATION | SCRIPPS RESEARCH INSTITUTE, THE | 2011-05-12 | — | — | US | disclosed |
| WO-2009064913-A1 | CHIMER CONTAINING A TARGETING PORTION LINKED TO A SCISSION-ACTIVATED DUOCARMYCIN-TYPE PRODRUG | THE SCRIPPS RESEARCH INSTITUTE (US) | 2009-05-22 | — | — | WO | disclosed |
| WO-2009064908-A1 | CBI DERIVATIVES SUBJECT TO REDUCTIVE ACTIVATION | THE SCRIPPS RESEARCH INSTITUTE (US) | 2009-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160016972-A1 | Cyclic N-Acyl O-Amino Phenol CBI Derivative | CCNI, DBI, SUB1 | ADH1A 2873/4885KIT 1087/4885FLT1 4774/4885 |
| US-20110112163-A1 | CBI DERIVATIVES SUBJECT TO REDUCTIVE ACTIVATION | DBI, CCNI, TDO2 | ADH1A 1873/4885KIT 1488/4885FLT1 4799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.